Emerging drugs and alternative possibilities in the treatment of tuberculosis

References

• Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev. 2008;1:1.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report 2015 [Updated 2015; cited 2015 Nov 10]. Available from: http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf?ua=1
   Google Scholar
• Centers for Disease Control and Prevention. Fact sheets.the difference between latent TB infection and TB disease. [cited 2015 Nov 11]. Available from: http://www.cdc.gov/tb/publications/factsheets/general/ltbiandactivetb.htm
   Google Scholar
• Caminero JA, Sotgiu G, Zumla A, et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10(9):621–629.
   PubMed Web of Science ®Google Scholar
• Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008;359(6):563–574.
   PubMed Web of Science ®Google Scholar
• Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2004;169(10):1103–1109.
   PubMed Web of Science ®Google Scholar
• Eker B, Ortmann J, Migliori GB, et al. Multidrug- and extensively drug-resistant tuberculosis, germany. Emerg Infect Dis. 2008;14(11):1700–1706.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio L, Centis R, Sotgiu G, et al. New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Research. 2015;1(1):00010–2015.
   Google Scholar
• Caminero J. Treatment of multidrug-resistant tuberculosis: evidence and controversies [review article]. Int J Tuberculosis Lung Dis. 2006;10(8):829–837.
   PubMed Web of Science ®Google Scholar
• Zumla A, Nahid P, Cole ST. Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013;12(5):388–404.
   PubMed Web of Science ®Google Scholar
• Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis. 2014;14(4):327–340.
   PubMed Web of Science ®Google Scholar
• van den Boogaard J, Kibiki GS, Kisanga ER, et al. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother. 2009;53(3):849–862.
   PubMed Web of Science ®Google Scholar
• Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998;158(1):157–161.
   PubMed Web of Science ®Google Scholar
• Global tuberculosis report 2014. [cited 2014 Nov 15]. Available from: http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1
   Google Scholar
• Albanna AS, Smith BM, Cowan D, et al. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J. 2013;42(3):721–732.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for the treatment of tuberculosis: fourth edition. [Updated 2010; cited 2015 Oct 23] Available from: http://www.who.int/tb/publications/2010/9789241547833/en/
   Google Scholar
• World Health Organization. Guidelines for treatment of tuberculosis: fourth edition; [cited 2015 Oct 23]. Available from: http://www.who.int/tb/publications/2010/9789241547833/en/
   Google Scholar
• Companion handbook to the WHO guidelines for the programmatic management of drug- resistant tuberculosis. [Updated 2014; cited 2015 Jun 3]. Available from: http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809_eng.pdf?ua=1&ua=1
   Google Scholar
• Jenum S, Dhanasekaran S, Lodha R, et al. Approaching a diagnostic point-of-care test for pediatric tuberculosis through evaluation of immune biomarkers across the clinical disease spectrum. Scientific Reports. 2016;6:18520.
   PubMed Web of Science ®Google Scholar
• Tupasi TE, Gupta R, Quelapio M, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the philippines. PLoS Med. 2006;3(9):e352.
   PubMed Web of Science ®Google Scholar
• An expanded DOTS framework for effective tuberculosis control. stop TB communicable disease. [cited 2015 Nov 2]. Available from: http://apps.who.int/iris/bitstream/10665/67232/1/WHO_CDS_TB_2002.297.pdf
   Google Scholar
• Cegielski JP, Dalton T, Yagui M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis. 2014;59(8):1049–1063.
   PubMed Web of Science ®Google Scholar
• Gupta R, Brenner J, Henry CL. Procurement of second-line anti-tuberculosis drugs for DOTS-plus pilot projects. WHO working group on DOTS-plus for MDR-TB. Geneva: WHO; 1999. p. 5–6
   Google Scholar
• Gunther G, Gomez GB, Lange C, et al. TBNET. Availability, price and affordability of anti-tuberculosis drugs in europe: a TBNET survey. Eur Respir J. 2015;45(4):1081–1088.
   PubMed Web of Science ®Google Scholar
• Joint meeting of the global GLC committee and the MDR-TB core group. Geneva, switzerland; 2013 Apr 18-19 [cited 2015 Nov 2]. Available from: http://apps.who.int/iris/bitstream/10665/85370/1/WHO_HTM_TB_2013.08_eng.pdf?ua=1
   Google Scholar
• Giffin R, Robinson S. Addressing the threat of drug-resistant tuberculosis: a realistic assessment of the challenge: workshop summary. Institute of Medicine. Washington (DC): National Academies Press; 2009. ISBN-13: 978-0-309-13044-8ISBN-10: 0-309-13044-1
   Google Scholar
• Taj pharmaceuticals limited. [cited 2015 Nov 2]. Available from: http://tajpharma.com/media/media_l/Indian%20Generic%20Manufacturing%20Company%20receives%20Food%20and%20Drug%20Administration%20approval%20for%20manufacturing%20of%20Generic%20Linezolid.pdf
   Google Scholar
• Tuberculosis research in the Netherlands: innovation to accelerate the global tuberculosis elimination. [cited 2015 Nov 3]. Available from: https://www.kncvtbc.org/uploaded/2015/10/TBC1538_Whitepaper_WEB.pdf.
   Google Scholar
• Global strategy and targets for tuberculosis prevention, care and control after 2015. WHO. [cited 2015 Nov 3]. Available from: http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_12-en.pdf?ua=1
   Google Scholar
• Zumla A, George A, Sharma V, et al. The WHO 2014 global tuberculosis report—further to go. Lancet Glob Health. 2015;3(1):e10–e12.
   PubMed Web of Science ®Google Scholar
• The global TB alliance. [cited 2015 Nov 3]. Available from: http://www.tballiance.org/about/mission.php
   Google Scholar
• National Institute of Allergy and Infectious Diseases. Multi-drug resistant tuberculosis(MDR-TB) and possible effective treatments. [Updated 2007 May 13; cited 2015 Nov 17]. Available from: http://www.niaid.nih.gov/topics/tuberculosis/Understanding/WhatIsTB/ScientificIllustrations/pages/multidrugresistantillustration.aspx
   Google Scholar
• Implementing the WHO stop TB strategy. A handbook for national tuberculosis control programme. [cited 2015 Nov 10]. Available from: http://apps.who.int/iris/bitstream/10665/43792/1/9789241546676_eng.pdf.
   Google Scholar
• McShane H. Tuberculosis vaccines: beyond bacille calmette-guerin. Philos Trans R Soc Lond B Biol Sci. 2011;366(1579):2782–2789.
   PubMed Web of Science ®Google Scholar
• Working group on new TB drugs. Drug pipeline. [cited 2015 Sep 22]. Available from: http://www.newtbdrugs.org/pipeline.php
   Google Scholar
• TB Alliance:Putting science to work for a faster TB care. Our pipeline; [cited 2015 Sep 22]. Available from: http://www.tballiance.org/pipeline/pipeline.php
   Google Scholar
• Mahajan R. Bedaquiline: first FDA-approved tuberculosis drug in 40 years. Int J Appl Basic Med Res. 2013;3(1):1.
   PubMedGoogle Scholar
• Janssen Pharmaceutical Companies. Anti-infective drugs advisory committee meeting briefing document TMC207 (bedaquiline) treatment of patients with MDR-TB NDA 204-384; [cited 2015 Feb 21]. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm329260.pdf
   Google Scholar
• World Health Organization. Introduction of bedaquiline for the treatment of multidrug-resistant tuberculosis at country level; implementation plan; [updated 2015 Apr; cited 2016 Jan 17]. Available from: http://www.who.int/tb/publications/WHO_BDQimplementationplan.pdf
   Google Scholar
• Szumowski JD, Lynch JB. Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Des Devel Ther. 2015;9:677.
   PubMed Web of Science ®Google Scholar
• Lewis JM, Sloan DJ. The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag. 2015;11:779.
   PubMed Web of Science ®Google Scholar
• Carroll MW, Jeon D, Mountz JM, et al. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2013;57(8):3903–3909.
   PubMed Web of Science ®Google Scholar
• Lin AH, Murray RW, Vidmar TJ, et al. The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin. Antimicrob Agents Chemother. 1997;41(10):2127–2131.
   PubMed Web of Science ®Google Scholar
• Wolter N, Smith AM, Farrell DJ, et al. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother. 2005;49(8):3554–3557.
   PubMed Web of Science ®Google Scholar
• Zurenko GE, Gibson JK, Shinabarger DL, et al. Oxazolidinones: a new class of antibacterials. Curr Opin Pharmacol. 2001;1(5):470–476.
   PubMedGoogle Scholar
• Richter E, Rusch-Gerdes S, Hillemann D. First linezolid-resistant clinical isolates of mycobacterium tuberculosis. Antimicrob Agents Chemother. 2007;51(4):1534–1536.
   PubMed Web of Science ®Google Scholar
• Sacksteder KA, Protopopova M, Barry CE, et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiology. 2012;7(7):823–837.
   PubMed Web of Science ®Google Scholar
• De Lorenzo S, Alffenaar JW, Sotgiu G, et al. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J. 2013;41(6):1386–1392.
   PubMed Web of Science ®Google Scholar
• Dawson R, Condos R, Tse D, et al. Immunomodulation with recombinant interferon-γ1b in pulmonary tuberculosis. 2009.
   Google Scholar
• Elliott AM, Halwiindi B, Bagshawe A, et al. Use of prednisolone in the treatment of HIV-positive tuberculosis patients. Q J Med. 1992;85(307–308):855–860.
   Google Scholar
• Elliott AM, Luzze H, Quigley MA, et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis. 2004;190(5):869–878.
   PubMed Web of Science ®Google Scholar
• Mathur ML. Potential utility of mycobacterium w vaccine in control of tuberculosis. Curr Respir Med Rev. 2006;2(2):183–188.
   Google Scholar
• Saini V, Raghuvanshi S, Talwar GP, et al. Polyphasic taxonomic analysis establishes mycobacterium indicus pranii as a distinct species. PLoS One. 2009;4(7):e6263–e6263.
   PubMed Web of Science ®Google Scholar
• Gupta A, Ahmad FJ, Ahmad F, et al. Efficacy of mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. Plos One. 2012;7(7):e39215.
   PubMed Web of Science ®Google Scholar
• Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121–1130.
   PubMed Web of Science ®Google Scholar
• National University Hospital Singapore . Safety and efficacy of blocking IL-4 with pascolizumab in patients receiving standard combination therapy for pulmonary tuberculosis (TB).ClinicalTrials.gov [internet]; [updated 2014Oct 14; cited 2015 Nov 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT01638520
   Google Scholar
• Batdelger D, Dandii D, Jirathitikal V, et al. Open-label trial of therapeutic immunization with oral V-5 immunitor (V5) vaccine in patients with chronic hepatitis C. Vaccine. 2008;26(22):2733–2737.
   PubMed Web of Science ®Google Scholar
• Arjanova OV, Prihoda ND, Yurchenko LV, et al. Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB. Immunotherapy. 2011;3(2):181–191.
   PubMed Web of Science ®Google Scholar
• Butov DA, Pashkov YN, Stepanenko AL, et al. Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB. J Immune Based Ther Vaccines. 2011;9:3-8518-9-3.
   PubMedGoogle Scholar
• Butov DA, Efremenko YV, Prihoda ND, et al. Randomized, placebo-controlled phase II trial of heat-killed mycobacterium vaccae (immodulon batch) formulated as an oral pill (V7). Immunotherapy. 2013;5(10):1047–1054.
   PubMed Web of Science ®Google Scholar
• Lisichansk Regional Tuberculosis Dispensary. TB immunotherapy trial with heat-killed M. vaccae (imm03). ClinicalTrials.gov [internet]; [updated 2015 Apr 16; cited 2015 Nov 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT01977768?term=NCT01977768&rank=1
   Google Scholar
• Ministry of Science and Technology, India. Efficacy and safety of immunomodulator as an adjunct therapy in new pulmonary tuberculosis(category I) patients. ClinicalTrials.gov [internet]; [updated 2013 Apr 25; cited 2015 Nov 11].
   Google Scholar
• Johnson JL, Hadad DJ, Dietze R, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med. 2009;180(6):558–563.
   PubMed Web of Science ®Google Scholar
• Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014;371(17):1577–1587.
   PubMed Web of Science ®Google Scholar
• Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med. 2014;371(17):1599–1608.
   PubMed Web of Science ®Google Scholar
• Knight GM, Gomez GB, Dodd PJ, et al. The impact and cost-effectiveness of a four-month regimen for first-line treatment of active tuberculosis in South Africa. Plos One. 2015;10(12).
   Web of Science ®Google Scholar
• Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13(1):27–35.
   PubMed Web of Science ®Google Scholar
• Boeree MJ, Diacon AH, Dawson R, et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015;191(9):1058–1065.
   PubMed Web of Science ®Google Scholar
• Ruslami R, Nijland HM, Alisjahbana B, et al. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2007;51(7):2546–2551.
   PubMed Web of Science ®Google Scholar
• Dorman SE, Savic RM, Goldberg S, et al. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med. 2015;191(3):333–343.
   PubMed Web of Science ®Google Scholar
• Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009;373(9670):1183–1189.
   PubMed Web of Science ®Google Scholar
• Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011;365(1):21–31.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Menon PA, Gopalan N, et al. Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial. PLoS One. 2012;7(12):e47400. doi:10.1371/journal.pone.0047400.
   Google Scholar
• White MC, Tulsky JP, Lee JR, et al. Isoniazid vs. rifampin for latent tuberculosis infection in jail inmates: toxicity and adherence. J Correct Health Care. 2012;18(2):131–142.
   PubMed Web of Science ®Google Scholar
• Blumberg HM, Burman WJ, Chaisson RE, et al. American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603–662.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Doherty TM, Onyebujoh P, et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis. 2009;9(3):162–172.
   PubMed Web of Science ®Google Scholar
• Lee MR, Tsai CJ, Wang WJ, et al. Plasma biomarkers can predict treatment response in tuberculosis patients: a prospective observational study. Medicine (Baltimore). 2015;94(39):e1628.
   PubMed Web of Science ®Google Scholar
• Nell AS, D’lom E, Bouic P, et al. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS One. 2014;9(2):e89612.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Forgus S, De Boever F, et al. Improved CD4 T cell responses to mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine. 2013;31(17):2196–2206.
   PubMed Web of Science ®Google Scholar
• Montoya J, Solon JA, Cunanan SRC, et al. A randomized, controlled dose-finding phase II study of the M72/AS01 candidate tuberculosis vaccine in healthy PPD-positive adults. J Clin Immunol. 2013;33(8):1360–1375.
   PubMed Web of Science ®Google Scholar
• Thacher EG, Cavassini M, Audran R, et al. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. AIDS. 2014;28(12):1769–1781.
   PubMed Web of Science ®Google Scholar
• Penn-Nicholson A, Geldenhuys H, Burny W, et al. Safety and immunogenicity of candidate vaccine M72/AS01 E in adolescents in a TB endemic setting. Vaccine. 2015;33(32):4025–4034.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Substudy of protocol TB-018 (NCT01755598): Collection and storage of biological samples for evaluation of correlates of TB (C-041-972). ClinicalTrials.gov [internet]; [updated 2015 Oct 12; cited 2015 Nov 11]. https://clinicaltrials.gov/ct2/show/NCT02097095?term=NCT01755598&rank=1
   Google Scholar
• Spertini F, Audran R, Lurati F, et al. The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study. Tuberculosis. 2013;93(2):179–188.
   PubMed Web of Science ®Google Scholar
• Churchyard GJ, Snowden MA, Hokey D, et al. The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4 T cell counts> 350 cells/mm 3. Vaccine. 2015;33(15):1890–1896.
   PubMed Web of Science ®Google Scholar
• Tameris M, Hokey D, Nduba V, et al. A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants. Vaccine. 2015;33(25):2944–2954.
   PubMed Web of Science ®Google Scholar
• Dietrich J, Aagaard C, Leah R, et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J Immunol. 2005;174(10):6332–6339.
   PubMed Web of Science ®Google Scholar
• Schellack C, Prinz K, Egyed A, et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine. 2006;24(26):5461–5472.
   PubMed Web of Science ®Google Scholar
• Geldenhuys H, Mearns H, Miles DJ, et al. The tuberculosis vaccine H4: IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: a randomized controlled trial. Vaccine. 2015;33(30):3592–3599.
   PubMed Web of Science ®Google Scholar
• Aeras. A randomized, placebo controlled, partially blinded phase II study to evaluate safety, immunogenicity, and prevention of infection with mycobacterium tuberculosis of AERAS-404 and BCG revaccination in healthy adolescents (040-404). ClinicalTrials.gov [internet]; [updated 2015 May 26; cited 2015 Nov 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT02075203?term=NCT02075203&rank=1
   Google Scholar
• Aeras. Phase 1/II, safety and immunogenicity study of AERAS-404 in BCG-primed infants (C-015-404). ClinicalTrials.gov [internet]; [updated 2015 Oct 7; cited 2015 Nov 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT01861730?term=NCT01861730&rank=1
   Google Scholar
• Aeras. A phase I/IIa safety & immunogenicity of AERAS-456 in HIV-negative adults with & without latent tuberculosis infection (C-035-456). ClinicalTrials.gov [internet]; [updated 2015 Oct 12; cited 2015 Nov 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT01865487?term=NCT01865487&rank=1
   Google Scholar
• Bertholet S, Ireton GC, Ordway DJ, et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant mycobacterium tuberculosis. Sci Transl Med. 2010;2(53):53ra74.
   PubMed Web of Science ®Google Scholar
• IDRI. Phase 2a ID93 + GLA-SE vaccine trial in TB patients after treatment completion. ClinicalTrials.gov [internet]; [updated 2015 Oct 12; cited 2015 Nov 11]. Available from: https://clinicaltrials.gov/ct2/show/NCT02465216?term=NCT02465216&rank=1
   Google Scholar
• McShane H, Pathan AA, Sander CR, et al. Recombinant modified vaccinia virus ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med. 2004;10(11):1240–1244.
   PubMed Web of Science ®Google Scholar
• Scriba TJ, Tameris M, Mansoor N, et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J Infect Dis. 2011;203(12):1832–1843.
   PubMed Web of Science ®Google Scholar
• Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet. 2013;381(9871):1021–1028.
   PubMed Web of Science ®Google Scholar
• Ndiaye BP, Thienemann F, Ota M, et al. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015;3(3):190–200.
   PubMed Web of Science ®Google Scholar
• Yang X, Chen Q, Li Y, et al. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: A meta-analysis. PLoS One. 2011;6(9):e23826.
   PubMed Web of Science ®Google Scholar
• Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. Phase III clinical study of efficacy and safety of vaccae™ to prevent tuberculosis. ClinicalTrials.gov [internet]; [updated 2015 May 18; cited 2015 Nov11]. Available from: https://clinicaltrials.gov/ct2/show/NCT01979900?term=NCT01979900&rank=1
   Google Scholar
• Vakzine Projekt Management GmbH. Study to evaluate safety and immunogenicity of VPM1002 in comparison with BCG in newborn infants in South Africa. ClinicalTrials.gov [internet]; [updated 2013 Oct 28; cited 2015 Nov 11]. https://clinicaltrials.gov/ct2/show/NCT01479972?term=NCT01479972&rank=1
   Google Scholar
• O’brien RJ, Nunn PP. The need for new drugs against tuberculosis: obstacles, opportunities, and next steps. Am J Respir Crit Care Med. 2001;163(5):1055–1058.
   PubMed Web of Science ®Google Scholar
• Blanc DC, Nunn P. Incentives and disincentives for new anti-tuberculosis drug development [Internet]. Geneva: World Health Organization; 2000. Available form: http://www.who.int/tdr/publications/documents/incentives-disincentives-anti-tuberculosis.pdf
   Google Scholar
• Lechartier B, Rybniker J, Zumla A, et al. Tuberculosis drug discovery in the post-post-genomic era. EMBO Mol Med. 2014;6(2):158–168.
   PubMed Web of Science ®Google Scholar
• Koul A, Arnoult E, Lounis N, et al. The challenge of new drug discovery for tuberculosis. Nature. 2011;469(7331):483–490.
   PubMed Web of Science ®Google Scholar
• Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med. 2004;170(10):1131–1134.
   PubMed Web of Science ®Google Scholar
• Nuermberger EL, Yoshimatsu T, Tyagi S, et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2004;169(3):421–426.
   PubMed Web of Science ®Google Scholar
• Prideaux B, Via LE, Zimmerman MD, et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med. 2015;21(10):1223–1227.
   PubMed Web of Science ®Google Scholar
• Alffenaar JC, Gumbo T. Aarnoutse RE. Acquired drug resistance: we can do more than we think! Clin Infect Dis. 2015;60(6):969–970.
   PubMed Web of Science ®Google Scholar
• Sturkenboom MG, Akkerman OW, Bolhuis MS, et al. Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future. Antimicrob Agents Chemother. 2015;59(4):2474–14.
   PubMed Web of Science ®Google Scholar
• Gumbo T, Gillespie S, Crook A, et al. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2015;2015(372):576–577.
   Google Scholar
• Phillips PP, Gillespie SH, Boeree M, et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis. 2012;205(Suppl 2):S250–S257.
   PubMed Web of Science ®Google Scholar